114 related articles for article (PubMed ID: 11061684)
1. Bufotenine: toward an understanding of possible psychoactive mechanisms.
McBride MC
J Psychoactive Drugs; 2000; 32(3):321-31. PubMed ID: 11061684
[TBL] [Abstract][Full Text] [Related]
2. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
[TBL] [Abstract][Full Text] [Related]
3. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
Kärkkäinen J; Forsström T; Tornaeus J; Wähälä K; Kiuru P; Honkanen A; Stenman UH; Turpeinen U; Hesso A
Scand J Clin Lab Invest; 2005; 65(3):189-99. PubMed ID: 16095048
[TBL] [Abstract][Full Text] [Related]
4. Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors.
Aghajanian GK; Hailgler HJ
Psychopharmacol Commun; 1975; 1(6):619-29. PubMed ID: 1063421
[TBL] [Abstract][Full Text] [Related]
5. Bufotenine esters.
Glennon RA; Gessner PK; Godse DD; Kline BJ
J Med Chem; 1979 Nov; 22(11):1414-6. PubMed ID: 533890
[TBL] [Abstract][Full Text] [Related]
6. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
[TBL] [Abstract][Full Text] [Related]
7. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution, metabolism and effects of bufotenine administered to rats.
Fuller RW; Snoddy HD; Perry KW
Neuropharmacology; 1995 Jul; 34(7):799-804. PubMed ID: 8532147
[TBL] [Abstract][Full Text] [Related]
9. Bufotenine reconsidered.
McLeod WR; Sitaram BR
Acta Psychiatr Scand; 1985 Nov; 72(5):447-50. PubMed ID: 4091027
[TBL] [Abstract][Full Text] [Related]
10. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
Roth BL; Choudhary MS; Khan N; Uluer AZ
J Pharmacol Exp Ther; 1997 Feb; 280(2):576-83. PubMed ID: 9023266
[TBL] [Abstract][Full Text] [Related]
11. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
12. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
13. Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches.
Paulke A; Kremer C; Wunder C; Achenbach J; Djahanschiri B; Elias A; Schwed JS; Hübner H; Gmeiner P; Proschak E; Toennes SW; Stark H
J Ethnopharmacol; 2013 Jul; 148(2):492-7. PubMed ID: 23665164
[TBL] [Abstract][Full Text] [Related]
14. Serotonin/dopamine interaction--focus on 5-HT2C receptor, a new target of psychotropic drugs.
Di Giovanni G; Di Matteo V; Esposito E
Indian J Exp Biol; 2002 Dec; 40(12):1344-52. PubMed ID: 12974395
[TBL] [Abstract][Full Text] [Related]
15. Carbon 11 labeling of the psychoactive drug o-methyl-bufotenine and its distribution in the animal organism.
Berger G; Mazière M; Marazano C; Comar D
Eur J Nucl Med; 1978 Apr; 3(2):101-4. PubMed ID: 750198
[TBL] [Abstract][Full Text] [Related]
16. Biological Effects and Biodistribution of Bufotenine on Mice.
Vigerelli H; Sciani JM; Eula MAC; Sato LA; Antoniazzi MM; Jared C; Pimenta DC
Biomed Res Int; 2018; 2018():1032638. PubMed ID: 29955598
[TBL] [Abstract][Full Text] [Related]
17. Hallucinogens, serotonin and obsessive-compulsive disorder.
Delgado PL; Moreno FA
J Psychoactive Drugs; 1998; 30(4):359-66. PubMed ID: 9924841
[TBL] [Abstract][Full Text] [Related]
18. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.
Wallach JV
Med Hypotheses; 2009 Jan; 72(1):91-4. PubMed ID: 18805646
[TBL] [Abstract][Full Text] [Related]
19. The influence of bufotenin on the feeding behavior and cerebral serotonin content in rats.
Uluitu M; Lazăr M; Catrinescu G
Physiologie; 1976; 13(2):145-53. PubMed ID: 821071
[TBL] [Abstract][Full Text] [Related]
20. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Monsma FJ; Shen Y; Ward RP; Hamblin MW; Sibley DR
Mol Pharmacol; 1993 Mar; 43(3):320-7. PubMed ID: 7680751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
